{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:18:55Z","timestamp":1777551535358,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40265-016-0645-5","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T09:43:04Z","timestamp":1475487784000},"page":"1559-1566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia"],"prefix":"10.1007","volume":"76","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian M.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,3]]},"reference":[{"issue":"9","key":"645_CR1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1176\/appi.ps.55.9.997","volume":"55","author":"SJ Keith","year":"2004","unstructured":"Keith SJ, Pani L, Nick B, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv. 2004;55(9):997\u20131005.","journal-title":"Psychiatr Serv"},{"key":"645_CR2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2147\/PPA.S53795","volume":"7","author":"G Kaplan","year":"2013","unstructured":"Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adher. 2013;7:1171\u201380.","journal-title":"Patient Prefer Adher."},{"issue":"2","key":"645_CR3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.schbul.a007076","volume":"30","author":"M Valenstein","year":"2004","unstructured":"Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30(2):255\u201364.","journal-title":"Schizophr Bull"},{"issue":"4","key":"645_CR4","first-page":"222","volume":"41","author":"N Daghistani","year":"2016","unstructured":"Daghistani N, Rey JA. Invega Trinza: the first four-times-a-year, long-acting injectable antipsychotic agent. P T. 2016;41(4):222\u20137.","journal-title":"P T."},{"issue":"12","key":"645_CR5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40263-015-0295-2","volume":"29","author":"LHN Lee","year":"2015","unstructured":"Lee LHN, Choi C, Collier AC, et al. The pharmacokinetics of second-generation long-acting injectable antipsychotics: limitations of monograph values. CNS Drugs. 2015;29(12):975\u201383.","journal-title":"CNS Drugs."},{"issue":"8","key":"645_CR6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40263-013-0083-9","volume":"27","author":"AS Rauch","year":"2013","unstructured":"Rauch AS, Fleischhacker WW. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs. 2013;27(8):637\u201352.","journal-title":"CNS Drugs."},{"issue":"3","key":"645_CR7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/11203810-000000000-00000","volume":"24","author":"SM Hoy","year":"2010","unstructured":"Hoy SM, Scott LJ, Keating GM. Intramuscular paliperidone palmitate. CNS Drugs. 2010;24(3):227\u201344.","journal-title":"CNS Drugs."},{"issue":"3","key":"645_CR8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/jcph.597","volume":"56","author":"P Ravenstijn","year":"2016","unstructured":"Ravenstijn P, Remmerie B, Eng C, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: a phase-1, single-dose, randomized, open-label study. J Clin Pharmacol. 2016;56(3):330\u20139.","journal-title":"J Clin Pharmacol"},{"key":"645_CR9","unstructured":"European Medicines Agency. Trevicta (paliperidone palmitate) prolonged release suspension for injection: EU summary of product characteristics. 2016. http:\/\/www.ema.europa.eu\/ . Accessed 14 Sep 2016."},{"key":"645_CR10","unstructured":"Janssen Pharmaceuticals Inc. Invega Trinza\u00ae (paliperidone palmitate) extended-release injectable suspension, for intramuscular use: US prescribing information. 2016. http:\/\/www.janssencns.com\/ . Accessed 14 Sep 2016."},{"issue":"11","key":"645_CR11","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1185\/03007995.2015.1085849","volume":"31","author":"S Gopal","year":"2015","unstructured":"Gopal S, Vermeulen A, Nandy P, et al. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Curr Med Res Opin. 2015;31(11):2043\u201354.","journal-title":"Curr Med Res Opin"},{"key":"645_CR12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","volume":"13","author":"HA Nasrallah","year":"2008","unstructured":"Nasrallah HA. Atypical antipsychotic-induced metabolite side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13:27\u201335.","journal-title":"Mol Psychiatry."},{"issue":"Suppl. 3","key":"645_CR13","first-page":"S386","volume":"15","author":"P Karlsson","year":"2005","unstructured":"Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects [abstract no. P.1.053]. Eur Neuropsychopharmacol. 2005;15(Suppl. 3):S386.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"645_CR14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1176\/appi.ajp.163.3.396","volume":"163","author":"G Remington","year":"2006","unstructured":"Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006;163(3):396\u2013401.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"645_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyw018","volume":"19","author":"AJ Savitz","year":"2016","unstructured":"Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016;19(7):1\u201314.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9 Suppl 1","key":"645_CR16","first-page":"353S","volume":"79","author":"MN Samtani","year":"2016","unstructured":"Samtani MN, Rossenu S, Vermeulen A, et al. Paliperidone palmitate 3-month dosing in special patient populations and derivation of secondary pharmacokinetic parameters based on simulations. Biol Psychiatry. 2016;79(9 Suppl 1):353S.","journal-title":"Biol Psychiatry"},{"issue":"4","key":"645_CR17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1124\/dmd.107.018275","volume":"36","author":"M Vermeir","year":"2008","unstructured":"Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36(4):769\u201379.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"645_CR18","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","volume":"72","author":"J Berwaerts","year":"2015","unstructured":"Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830\u20139.","journal-title":"JAMA Psychiatry."},{"issue":"9 Suppl 1","key":"645_CR19","first-page":"352S","volume":"79","author":"M Mathews","year":"2016","unstructured":"Mathews M, Nuamah I, Savitz A, et al. Comparison of 3-monthly versus 1-monthly paliperidone palmitate for time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia. Biol Psychiatry. 2016;79(9 Suppl 1):352S\u20133S.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"645_CR20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71\u201393.","journal-title":"Schizophr Bull"},{"key":"645_CR21","unstructured":"National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. 2014. http:\/\/www.nice.org.uk . Accessed 23 Aug 2016."},{"issue":"1","key":"645_CR22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","volume":"14","author":"A Hasan","year":"2013","unstructured":"Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2\u201344.","journal-title":"World J Biol Psychiatry."},{"issue":"9 Suppl 1","key":"645_CR23","first-page":"202S","volume":"77","author":"L Alphs","year":"2015","unstructured":"Alphs L, Turkoz I, Fu DJ. Design of the schizophrenia disease recovery evaluation and modification (DREaM) study. Biol Psychiatry. 2015;77(9 Suppl 1):202S.","journal-title":"Biol Psychiatry"},{"issue":"9 Suppl 1","key":"645_CR24","first-page":"213S","volume":"79","author":"S Gopal","year":"2016","unstructured":"Gopal S, Xu H, McQuarrie K, et al. Caregiver burden in schizophrenia: pooled analysis of the involvement evaluation questionnaire data for paliperidone palmitate 3-month formulation. Biol Psychiatry. 2016;79(9 Suppl 1):213S.","journal-title":"Biol Psychiatry"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0645-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0645-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0645-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T00:13:38Z","timestamp":1498349618000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0645-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":24,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0645-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}